Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.32 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4574337 | 0.88 | PDE4D (0.38) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL73651 | 0.86 | PDE4A (0.41) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL73466 | 0.80 | ALDH1A1 (0.40) | NPC1RAB9AALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL73967 | 0.77 | PDE4B (0.42) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL5506611 | 0.77 | PDE4A (0.40) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL72181 | 0.75 | MGAM (0.43) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL5018032 | 0.74 | PDE4B (0.46) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL4574940 | 0.74 | NPC1 (0.36) | PDE4DPDE4BPDE4APDE4CNPC1 | |
| SCHEMBL3877963 | 0.73 | PDE4A (0.35) | PDE4DPDE4BPDE4APDE4CALDH1A1 | |
| SCHEMBL73653 | 0.72 | PDE4B (0.44) | PDE4DPDE4BPDE4APDE4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | claimed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | claimed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | claimed |
| EP-1831227-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | GLENMARK PHARMACEUTICALS SA (CH) | 2013-06-19 | — | — | EP | disclosed |
| US-8129401-B2 | Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7943634-B2 | Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306082-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | PDE4D 11/4885PDE4B 6/4885PDE4A 3/4885 |
| US-20110190303-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PTGER4, NOX4, PDE4A | PDE4D 10/4885PDE4B 6/4885PDE4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.